Cebiotex, a CataloniaBio member, has launched a new crowdequity campaign to raise €650,000 through CapitalCell in order to ensure its first drug, CEB-01 for post-op treatment of soft-tissue sarcomas, reaches paediatric oncology.
The campaign is part of a €1.6-million round of funding. The biotech firm hopes this capital will be covered with public and private funds, allowing it to begin phase I/II clinical trials on candidate CEB-01 with 15 patients in 2018, and begin proof-of concept testing for new oncology treatments for pancreatic cancer, liver cancer and brain tumours. “The first licences are expected from 2021, with potential for seven-fold profitability”, says Joan Bertran, co-founder and CEO of Cebiotex.
CEB-01 is the company’s first project developed using its Cebiotex® technology platform, which is a biomedical application of biodegradable nanofibers as a local drug-delivery system.
Cebiotex is a spin-off created in 2012 by researchers from the Polytechnic University of Catalonia (UPC) and Hospital Sant Joan de Déu (HSJD). The company is based at the Barcelona Science Park (PCB). Since it was created, the biotechnology firm has raised more than €2 million in public and private funds.
Photo: Joan Bertran, CEO of Cebiotex at the Barcelona Science Park - ©Cebiotex
Comments